Soy Isoflavones

The Honest Version of the Isoflavone Story

Isoflavones are the most-researched supplement in the menopause space, and reading that research carefully produces a conclusion that satisfies nobody: they do something real, the something is small, and it takes far longer to arrive than any label suggests.

A model-based meta-analysis of 16 trials in about 1,710 women put a number on it. After subtracting the placebo effect, the maximum hot-flash reduction attributable to isoflavones was 25.2% — which the same model scaled against estradiol's maximum of 44.9%. Isoflavones deliver roughly 57% of estradiol's ceiling.

The second number from that model matters more, and it is the one almost nobody acts on. Isoflavones needed 13.4 weeks to reach half of their maximal effect, against 3.09 weeks for estradiol, and roughly 48 weeks to reach 80% of maximum. Most published isoflavone trials ran twelve weeks. They stopped measuring before the intervention had finished working.

The JAMA meta-analysis of plant-based therapies — 62 studies, 6,653 women — reached the same territory from a different direction: soy isoflavones specifically were associated with 0.79 fewer hot flashes per day (95% CI −1.35 to −0.23), and improvement in vaginal dryness, but no significant reduction in night sweats. That review also flagged that 74% of the included trials carried a high risk of bias in three or more domains.

The Equol Problem

Here is why trials disagree with each other, and why your neighbour's experience predicts nothing about yours.

Daidzein, one of the two main soy isoflavones, is not the active molecule. Gut bacteria convert it into S-equol, which binds ER-β with much greater affinity and hangs around longer. Whether you can perform that conversion is a property of your microbiome, not your dose.

Roughly a third of Western women are equol producers. In a cross-sectional study of 365 midlife women with regular soy intake, 129 (35%) produced equol. Among those producers, women in the highest quartile of dietary daidzein intake were 76% less likely to report above-average vasomotor symptoms (OR 0.24; 95% CI 0.07–0.83). Among non-producers, dietary daidzein showed no association at all with symptom frequency.

Randomise a mixed population of producers and non-producers and you dilute a real effect into a marginal one. That is a plausible reading of the entire isoflavone literature.

The workaround is to supply equol directly. A meta-analysis of six equol trials (779 subjects) found a significant benefit for hot-flash scores in non-producers. The 12-week Japanese RCT that first tested a purpose-built S-equol supplement — 134 women, 10 mg once versus three times daily versus placebo — found its clearest wins in mood-related outcomes: tension-anxiety, depression-dejection, fatigue and vigour all improved against placebo. Read honestly, S-equol's best-supported claim is mood and general climacteric score, not hot-flash count.

What the Position Statements Say

This is where a supplement page has to be straight with the reader. The North American Menopause Society's 2023 nonhormone therapy position statement does not recommend soy foods, soy extracts, or the soy metabolite equol for vasomotor symptoms (Level II evidence). It also declines to recommend supplements and herbal remedies generally.

What it does recommend at Level I: cognitive-behavioural therapy, clinical hypnosis, SSRIs and SNRIs, gabapentin, and fezolinetant. And it states plainly that hormone therapy remains the most effective treatment for vasomotor symptoms.

So the defensible position on isoflavones is not "the natural alternative to HRT." It is: a low-risk option with a small, slow, genuinely measurable effect, worth a twelve-month trial for a woman who cannot or will not take hormone therapy — with clear eyes about the size of the prize.

Where the Evidence Is Actually Stronger: Bone

Vasomotor symptoms get the marketing. Bone is where isoflavones have the steadier signal. Meta-analyses of randomised trials report preservation of lumbar spine bone mineral density and reductions in bone-resorption markers in postmenopausal women.

That matters because of when bone is lost. In the SWAN cohort, bone loss began one year before the final menstrual period and decelerated two years after it. Cumulative ten-year lumbar spine loss was 10.6%, of which 7.38% was lost during that three-year transmenopausal window. Femoral neck loss was 9.1% cumulative, 5.8% during transmenopause.

If you are going to intervene on bone, the window is narrow and it opens before the periods stop — which is covered in the bone and arterial longevity protocol.

Dosing

Safety

Isoflavones sit at safety tier A. Trials to twelve months report adverse events at placebo rates. The perennial breast-cancer worry rests on ER-alpha reasoning that the ER-β selectivity argues against, and observational data in survivors have been reassuring rather than alarming — but a woman with active hormone-sensitive disease, or on tamoxifen, should route this through her oncologist rather than a supplement label.

The one interaction to actually respect is levothyroxine absorption, which is a real and well-documented effect of soy protein. Separate them.

Related Research

• Perimenopause Supplements: What the Evidence Actually Supports
• The Menopause Transition Protocol
• Estrogen Metabolism: DIM and Calcium-D-Glucarate Explained